Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial Hypertension. [electronic resource]
Producer: 20170710Description: 7901-14 p. digitalISSN:- 1520-4804
- Administration, Inhalation
- Airway Remodeling -- drug effects
- Animals
- Cell Line
- Cell Proliferation
- Hypertension, Pulmonary -- drug therapy
- Lung -- blood supply
- Membranes, Artificial
- Molecular Docking Simulation
- Muscle, Smooth, Vascular -- drug effects
- Niacinamide -- analogs & derivatives
- Permeability
- Proto-Oncogene Proteins c-kit -- antagonists & inhibitors
- Pyrazoles -- chemical synthesis
- Rats
- Receptor, Platelet-Derived Growth Factor alpha -- antagonists & inhibitors
- Receptor, Platelet-Derived Growth Factor beta -- antagonists & inhibitors
- Receptors, Platelet-Derived Growth Factor -- antagonists & inhibitors
- Structure-Activity Relationship
- Vascular Remodeling -- drug effects
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.